-$26.72
$26.89
bear -$26.72
base -$11.86
bull $26.89
margin of safety $10.00
market price* $13.04
Business condition attached to the margin of safety
Two consecutive quarters in which total revenue grows year over year (as reported in the company's quarterly filings), with term-loan principal at or below $425 million.
WHAT THE BUSINESS IS. WW International (WeightWatchers) sells weight-management subscriptions. The Behavioral business (the points-based program, app, coaching and workshops) produced $592.6 million of subscription revenue in 2025; the Clinical business (WW Clinic, built on the 2023 Sequence telehealth acquisition, which prescribes and manages GLP-1 and other weight-loss medications) produced $112.8 million. About 70% of revenue is booked in the United States, about 10% in Germany, about 4% in Canada and the rest mainly in the United Kingdom, France, Australia and other international markets. The core problem is the spread of GLP-1 drugs: total revenue fell from $1.41 billion in 2019 to $711 million in 2025, Behavioral subscribers fell 18.9% in 2025 to 2.63 million, and revenue was down another 10% in the first quarter of 2026 and 14% in the second. Clinical subscribers grew 41.9% to 130,000 but are still small. WHAT HAPPENED TO THE CAPITAL STRUCTURE. The company went through a prepackaged Chapter 11 and emerged on June 24, 2025. About $1.4 billion of debt was replaced with a $465 million term loan due June 24, 2030, priced at Term SOFR plus 6.80% (roughly 10.5% today). Lenders received 91% of the new stock and the old shareholders 9%, so there are now about 10.0 million shares, subject to dilution from a management incentive plan. The loan requires the company to pay down debt with cash above $100 million each year. In the second quarter of 2026 the company repurchased about $41 million of the loan for about $37 million, booking a $4.6 million gain, which shows the loan trades below face value. At June 30, 2026 the company owed $423.6 million and held $101.5 million of cash. The company has no going-concern warning; its 2025 annual report concludes it has enough liquidity for at least the next twelve months. HOW WE MEASURED EARNING POWER. We measure the cash the business generates for all of its capital providers before interest: operating cash flow, less working-capital swings, stock compensation and capital spending (including capitalized software, the company's main investment), plus cash interest. On that basis the business produced about $34 million in 2023, $66 million in 2024 and $52 million in 2025. The 2025 figure includes $40.7 million of one-time bankruptcy professional fees; without them it was about $93 million, helped by deep cost cuts. Earlier years, when revenue was $1.2 to $1.5 billion, describe a much larger business and are left out. The middle of the 2023 to 2025 range, about $66 million a year, is our starting point. Two accounting choices matter. First, the reorganization revalued the brand and customer assets, which created about $100 million a year of amortization. It is a non-cash charge and is not deducted; the real wearing-out of the brand is carried instead in the declines assumed in every case. Second, the 2025 tax charge was split oddly between the periods before and after emergence, so we used the full-year combined figures. RECENT RESULTS. The first half of 2026 was much weaker. Our estimate of cash generation before interest is about $15 million, against about $31 million in the first half of 2025. Gross profit fell $31 million and marketing rose $30 million (to $140.8 million), partly offset by lower overhead. Including the weak second half of 2025, that is three soft quarters in a row. So the coming year starts below the starting point: about $50 million, compared with a normalized 2025 that grew about 40% on lower costs. We assume no growth in Clinical in any case, because it is a new business that has not yet proven it can keep growing. BASE CASE. Behavioral keeps shrinking roughly as it has since 2022 (revenue down 10% to 14% a year), Clinical holds its size, and management keeps cutting costs in line with revenue, as it did in 2024 and 2025. Cash generation before interest is about $50 million in the coming year and falls about 10% a year after that, with no point at which it stabilizes, because nothing in the filings yet shows the subscriber decline ending. The business is worth about $313 million. Against that it owes about $431 million: $423.6 million of loan, plus about $59 million for the cost of paying roughly 10.5% interest rather than a normal rate until 2030, minus about $52 million of cash beyond what the business needs to operate. The shortfall is about $119 million, or about -$11.86 a share. Put plainly, in the middle case the company owes more than it is worth. Its cash generation of about $45 to $50 million barely covers about $45 million of annual interest today and falls short within two years, so refinancing the full loan in 2030 is unlikely without a large write-down for shareholders. BEAR CASE. The decline continues and a consumer recession is added, like 2008 to 2009, when the company's revenue fell about 9%. More oral and cheaper GLP-1 options speed up subscriber losses. Cash generation is about $38 million in the coming year, falls 25% in the recession year and then about 15% a year. The business is worth about $164 million against about $431 million owed, so it owes about $267 million more than it is worth, about -$26.72 a share. Lenders would almost certainly take control before or at the 2030 maturity. BULL CASE. Management brings marketing back to its 2025 level (about $30 million a year less than the 2026 pace), keeps overhead low, and Clinical growth offsets enough of the Behavioral decline that cash generation starts at about $70 million and falls only about 4% a year. That is comfortably above the interest bill, so the loan can be paid down and refinanced in 2030. The business is worth about $700 million; less about $431 million owed, that leaves about $269 million, or about $26.89 a share before any dilution from the management incentive plan. WHAT WOULD MAKE THIS WRONG. On the upside: subscribers stop falling, or Clinical keeps growing fast enough to lift total revenue. On the downside: faster subscriber losses, or a repeat of the 2024 franchise-rights write-downs ($315 million) as the brand's value keeps eroding. One item could not be fully reconciled. Working-capital detail for the first half of 2026 comes from the quarterly filing's tagged data, which leaves a gap of about $3 million to reported operating cash flow. It does not change the conclusion. Our previous figures were prepared on a different basis and are not comparable. MARGIN-OF-SAFETY PRICE. We are fairly confident of the earnings level, because several years of filings agree, but the direction is clearly down. The worst plausible outcome is that subscriber losses continue through the 2030 maturity: a business producing $30 million or less cannot carry a $424 million floating-rate loan, so the shares would be wiped out in a second restructuring. Being wrong about the speed of decline, Clinical's staying power or the refinancing could swing the shares from nothing to the high twenties. The company pays no dividend, and excess cash goes to lenders first, so nothing is paid to owners over the holding period. In the base and bear cases the shares are worth nothing, so on today's facts no margin-of-safety price applies. If total revenue grows year over year for two consecutive quarters, the business would show it can hold about $50 million of cash generation. In that case it would be worth roughly $40 a share after debt, and even a $40 million level would support about $24. At $10 a share, all of the equity is valued at about $100 million. From that price, a stabilized business would only need to reach about $20 a share by the 2030 refinancing for the implied return to be 20% a year, which leaves room for being partly wrong. The margin-of-safety price of $10 applies only once that condition is met.